Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (21-30 of 567) with videos related to

Pageof 57
Sort By:
Clinical Pharmacology and Therapeutics|January 23, 2014
Integrated efficacy to effectiveness trialsR M Califf
American Heart Journal|March 31, 2000
Chronic ischemic heart diseaseM Gent, R M Califf
Circulation|February 1, 1992
TIMI IIB follow-up. Lessons for clinicians and investigatorsR M Califf, C Granger
North Carolina Medical Journal|September 1, 1988
Heart attackM Munster, R M Califf
American Heart Journal|December 2, 2000
Critical concepts in cost-effectiveness for cardiovascular specialistsR M Califf, E L Eisenstein
JAMA|March 14, 2000
Beta-blocker therapy for heart failure: the evidence is in, now the work beginsR M Califf, C M O'Connor
American Heart Journal|January 1, 1997
Our vision for the American Heart JournalR M Califf, D B Mark
The American Journal of Cardiology|December 19, 1996
How much do we gain by reducing time to reperfusion therapy?R M Califf, L K Newby
Seminars in Thoracic and Cardiovascular Surgery|April 1, 1994
Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular DiseasesR M Califf, D B Mark
Journal of the American College of Cardiology|June 1, 1989
Tissue plasminogen activator: why the backlash?E J Topol, R M Califf
Pageof 57

Showing results (21-30 of 567) with videos related to

Sort By:
Pageof 57
Clinical Pharmacology and Therapeutics|January 23, 2014
Integrated efficacy to effectiveness trialsR M Califf
American Heart Journal|March 31, 2000
Chronic ischemic heart diseaseM Gent, R M Califf
Circulation|February 1, 1992
TIMI IIB follow-up. Lessons for clinicians and investigatorsR M Califf, C Granger
North Carolina Medical Journal|September 1, 1988
Heart attackM Munster, R M Califf
American Heart Journal|December 2, 2000
Critical concepts in cost-effectiveness for cardiovascular specialistsR M Califf, E L Eisenstein
JAMA|March 14, 2000
Beta-blocker therapy for heart failure: the evidence is in, now the work beginsR M Califf, C M O'Connor
American Heart Journal|January 1, 1997
Our vision for the American Heart JournalR M Califf, D B Mark
The American Journal of Cardiology|December 19, 1996
How much do we gain by reducing time to reperfusion therapy?R M Califf, L K Newby
Seminars in Thoracic and Cardiovascular Surgery|April 1, 1994
Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular DiseasesR M Califf, D B Mark
Journal of the American College of Cardiology|June 1, 1989
Tissue plasminogen activator: why the backlash?E J Topol, R M Califf
Pageof 57